The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
Career conservative and former congressman Dave Weldon will, if confirmed, act as director of the Centers of Disease Control ...
With two decisions originally scheduled for this week already announced, including BridgeBio's approval in ATTR-CM, the ...
ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...
Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...
Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than Pfizer’s already established tafamidis. The only targeted treatment option ...
RFK Jr. as HHS head is perhaps President-elect Donald Trump’s most controversial Cabinet pick now that Matt Gaetz has ...
A Reuters report on Friday revealed that FDA researchers have found additional molecular evidence tying blockbuster asthma ...
AstraZeneca Fends Off Adcomm’s Safety Concerns on Andexxa, Axes Mid-Stage Opioid Use Disorder Drug
The pharma is seeking full approval for its anticoagulation reversal drug Andexxa, which the FDA granted accelerated approval ...
Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster ...
Massachusetts’ increased investment in the life sciences industry includes boosting its life sciences tax incentive program ...
In this episode of Denatured, BioSpace's Head of Insights Lori and guests from Teva Pharmaceuticals and TOWER Capital Group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback